UNSPSC 51263600: Adrenergic blocking agent quinazolines

This classification denotes adrenergic blocking agents made from benzopyrimidines, or compounds consisting of two six-membered rings, one benzene, one pyrimidine ring.

UNSPSC 51263600 Adrenergic blocking agent quinazolines is a Class code, but the recent state and local procurement activity recorded under it does not align with the code's pharmaceutical scope. Seminole County, Florida posted an IFB in June 2026 for naloxone and drug deactivation systems—opioid-overdose reversal agents and harm-reduction equipment—which fall outside the adrenergic blocking agent quinazoline family. The source shows no additional opportunities under this code, and the single record appears to reflect a tagging mismatch rather than typical activity under the code's nominal definition.

The Seminole County solicitation (IFB 60459723LAS, due July 26, 2026) calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The contract structure includes a two-year initial term with a one-year renewal option, fixed-fee pricing, and standard compliance requirements including E-Verify, drug-free workplace certification, workers' compensation, commercial general liability, and professional liability insurance. FEMA funding was noted as a potential source, which would trigger additional federal regulatory compliance. No explicit set-aside designations are referenced. The code shows no meaningful recent activity in state and local procurement beyond this single opportunity, suggesting either limited demand for adrenergic blocking agent quinazolines among public bodies or systematic miscoding in the procurement database.